AR115529A1 - Heparina ld para el tratamiento y prevención secundaria de accidente cerebrovascular isquémico - Google Patents

Heparina ld para el tratamiento y prevención secundaria de accidente cerebrovascular isquémico

Info

Publication number
AR115529A1
AR115529A1 ARP190101617A ARP190101617A AR115529A1 AR 115529 A1 AR115529 A1 AR 115529A1 AR P190101617 A ARP190101617 A AR P190101617A AR P190101617 A ARP190101617 A AR P190101617A AR 115529 A1 AR115529 A1 AR 115529A1
Authority
AR
Argentina
Prior art keywords
treatment
heparin
secondary prevention
cerebrovascular ischemic
ischemic accident
Prior art date
Application number
ARP190101617A
Other languages
English (en)
Inventor
Dieter Welzel
Original Assignee
Fytagoras B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fytagoras B V filed Critical Fytagoras B V
Publication of AR115529A1 publication Critical patent/AR115529A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Reivindicación 1: Heparina de peso molecular medio para su uso en el tratamiento y/o prevención secundaria del accidente cerebrovascular isquémico.
ARP190101617A 2018-06-14 2019-06-12 Heparina ld para el tratamiento y prevención secundaria de accidente cerebrovascular isquémico AR115529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18177815.0A EP3581189A1 (en) 2018-06-14 2018-06-14 Medium molecular weight heparin for treatment and secondary prevention of ischemic stroke

Publications (1)

Publication Number Publication Date
AR115529A1 true AR115529A1 (es) 2021-01-27

Family

ID=62684610

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101617A AR115529A1 (es) 2018-06-14 2019-06-12 Heparina ld para el tratamiento y prevención secundaria de accidente cerebrovascular isquémico

Country Status (7)

Country Link
US (1) US20210228617A1 (es)
EP (1) EP3581189A1 (es)
CN (1) CN114096259A (es)
AR (1) AR115529A1 (es)
DE (1) DE112019002992T5 (es)
TW (1) TW202015705A (es)
WO (1) WO2019238770A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112398838B (zh) * 2020-11-06 2022-09-23 支付宝(杭州)信息技术有限公司 一种基于隐私保护的认证方法、装置、设备及存储介质

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201712A3 (en) * 1999-06-30 2003-03-28 Weitz Jeffrey I Ancaster Clot associated coagulation factors inhibiting heparin compositions
ES2231303T3 (es) * 2000-01-10 2005-05-16 Dieter Welzel Heparina con masa molecular media.
EP3348270A1 (en) * 2017-01-11 2018-07-18 Fytagoras B.V. Medium molecular weight heparin

Also Published As

Publication number Publication date
TW202015705A (zh) 2020-05-01
DE112019002992T5 (de) 2021-02-25
US20210228617A1 (en) 2021-07-29
CN114096259A (zh) 2022-02-25
WO2019238770A1 (en) 2019-12-19
EP3581189A1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
CO2018012996A2 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CO2018013557A2 (es) Composiciones que comprenden cepas bacterianas
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
CO2018004315A2 (es) Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CL2019001740A1 (es) Novedoso conjugado de amanitina.
CR20170095A (es) Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
CO2021004456A2 (es) Vacunas neumocócicas multivalentes
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
ES2970224T3 (es) Tinostamustina para su uso en el tratamiento del sarcoma
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CL2018003417A1 (es) Nuevos compuestos.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2017000563A1 (es) Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia.
AR115529A1 (es) Heparina ld para el tratamiento y prevención secundaria de accidente cerebrovascular isquémico
AR106981A1 (es) Una composición antimicrobiana

Legal Events

Date Code Title Description
FB Suspension of granting procedure